Moleculin Biotech raises millions, Bellicum ... Feb 07, 2020 · Bellicum's stock price closed at $1.20 per share on Feb. 5, according to Yahoo Finance. After the split, the pharmaceutical company's stock closed at $10.28 per share on Feb. 6. MBRX Moleculin Biotech, Inc. Stock Quote Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) and lung-localized tumors. Moleculin... (MBRX) Stock Price VWAP | Premarket | After Hours
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).
Find the latest Moleculin Biotech, Inc. (MBRX) stock discussions in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. Moleculin Biotech raises millions, Bellicum ... Feb 07, 2020 · Bellicum's stock price closed at $1.20 per share on Feb. 5, according to Yahoo Finance. After the split, the pharmaceutical company's stock closed at $10.28 per share on Feb. 6. MBRX Moleculin Biotech, Inc. Stock Quote Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) and lung-localized tumors.
Exploring Moleculin Biotech (NASDAQ:MBRX) stock? View MBRX's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings
A clinical-stage pharmaceutical company focused on the development of game-changing oncology drug candidates Moleculin Biotech, Inc. (MBRX) Social Stream - Stock News Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Moleculin down 51% on direct equity offering (NASDAQ:MBRX ... Apr 23, 2019 · Moleculin Biotech (NASDAQ:MBRX) inks agreements with institutional investors to purchase an aggregate of 9,375,000 units at $1.60 per unit …
What's going on at Moleculin Biotech (NASDAQ:MBRX)? View breaking news headlines for MBRX stock from trusted media outlets at MarketBeat.
Exploring Moleculin Biotech (NASDAQ:MBRX) stock? View MBRX's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings Moleculin Biotech, Inc. Common Stock (MBRX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global In depth view into MBRX (Moleculin Biotech) stock including the latest price, Yahoo. The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential
Allscripts - MDRX - Stock Price & News | The Motley Fool
A clinical-stage pharmaceutical company focused on the development of game-changing oncology drug candidates Moleculin Biotech, Inc. (MBRX) Social Stream - Stock News Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Moleculin down 51% on direct equity offering (NASDAQ:MBRX ...